Drug Trial Radar · NCT07330310
A Phase 3 Trial of JKN2401 Injection in COPD
Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
888
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Sep 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Joincare Pharmaceutical Group Industry Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
JKN2401 InjectionBiological
JKN2401 subcutaneous injection, Q4W
PlaceboOther
Placebo subcutaneous injection,Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualised rate of moderate or severe COPD exacerbationsTime frame: during 52 weeks of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.